OBJECTIVES: Anemia is one of the most commonly occurring co-morbidity in patients of chronic kidney disease (CKD) which can leads to adverse clinical outcomes. This study was carried out to assess the prevalence and management of anemia in patients diagnosed with chronic kidney disease. METHODS: A cross sectional study was carried out in CKD patients of all age for a period of two year from Sept 2014 to 2015, at a tertiary care hospital. Patients with serum creatinine more than 1.2mg/dL were included. According to WHO, anemia in male >15 years were categorized into mild (110-129g/l) moderated (80-109g/l) and severe (lower than 80g/l) on the basis of Hemoglobin levels. In females, mild (110-119g/l) moderated (80-109g/l) and severe (lower than 80g/l). Binary logistic regression was used for analysis. RESULTS: A total of 408 CKD patients (Mean age: 52.05±12.4Y) were enrolled for study purpose. According to WHO anemia definition, the number of male patients diagnosed with mild, moderate and severe anemia were 26%(N=58), 30%(N=66) and 36%(N=80), respectively. In females the prevalence of mild, moderate and severe were 10%(N=19), 47%(N=89), 22%(N=42). Anemia was found to be most prevalence in CKD V (95%) followed by patients in CKD IV, III and II stages (91%, 85%, 77%, and 68%, respectively). Of all, 87% of the patients were diagnosed with anemia. Combination of vitamin B 12+iron+folic acid was found to be most commonly prescribed to 98% of the patients, followed by iron injection, folic acid and erythropoietin injection (17%, 9%, and 11%, respectively). The likelihood of anemia was significantly higher in patients over 60 yrs (OR 1.21, 1.09-2.41; p<0.05). CONCLUSIONS: Out of total 408 patients, 122 (30%) were diagnosed with severe anemia. Iron in combination with vitamin B 12 and folic acid were found to be most commonly prescribed. Elderly patients were found at higher risk of anemia.